Actively Recruiting
Radiation Treatment Using SABR for Men With Oligoprogressive Metastatic Castration-Resistant Prostate Cancer on Abiraterone Therapy
Led by Sunnybrook Health Sciences Centre · Updated on 2024-04-12
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating stereotactic ablative body radiotherapy SABR as a treatment for men with metastatic castration-resistant prostate cancer mCRPC who have oligoprogressive disease while on abiraterone therapy. Oligoprogression means a few metastatic tumors worsen while others remain stable or respond to treatment. This study aims to see if SABR can delay the need to switch systemic therapy and improve progression-free survival in this setting. The trial also focuses on measuring the safety of SABR in this group of patients. Participants will receive SABR directed at all progressive metastatic sites identified on conventional imaging. Standard SABR doses are used depending on the location of metastases, such as 35 Gy in 5 fractions for the prostate, 30-40 Gy in 5 fractions for non-spine bone metastases, and appropriate doses for spine, lymph nodes, brain, lung, liver, and adrenal metastases. Patients will continue taking abiraterone during and after the SABR treatments. Throughout the study, participants will be monitored for SABR-related toxicities up to 12 months and progression-free survival over 24 months. Additional assessments include biochemical progression, time to change of systemic therapy, radiographic control of treated areas, distant progression-free survival, overall survival up to 36 months, and quality of life evaluations. The study is sponsored by Sunnybrook Health Sciences Centre and involves ongoing follow-up to understand SABRs effects in this patient group.
CONDITIONS
Brief Title
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
Research Team
U
Urban Emmenegger, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here